Who is sponsoring NCT03061045?

NCT03061045 is sponsored by Johns Hopkins University.

What condition does NCT03061045 study?

NCT03061045 studies Neonatal Post-Hemorrhagic Hydrocephalus.

Is NCT03061045 still recruiting?

NCT03061045 is currently withdrawn. Last updated 25 January 2018.

Last reviewed 2018-01-25 · How we verify

NCT03061045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus

Withdrawn Phase 4 Last updated 25 January 2018

What this trial tests

Phase 4 trial testing Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON] in Neonatal Post-Hemorrhagic Hydrocephalus. Withdrawn.

Timeline

1 April 2017

Primary endpoint
22 January 2018

22 January 2018

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Start date	1 April 2017
Primary completion	22 January 2018
Estimated completion	22 January 2018

Drugs / interventions tested

Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON] — full drug profile →

Conditions studied

Neonatal Post-Hemorrhagic Hydrocephalus — all drugs for Neonatal Post-Hemorrhagic Hydrocephalus →

Sponsor

Johns Hopkins University

Who can join

Under 1, any sex, with Neonatal Post-Hemorrhagic Hydrocephalus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the proposed project is therefore to utilize the CEUS technique to assess cerebral perfusion changes before and after ventricular shunting in neonatal cases of PHH. The expectation of the proposed project is to validate statistically significant cerebral perfusion differences before and after shunting in neonates with PHH, as a preliminary feasibility study prior to conducting a large scale, prospective clinical trial incorporating therapeutic interventions using the CEUS technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]

Trials testing the same drug.

NCT03490929 — CEUS for Blunt Abdominal Trauma in Children · Phase 4 · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03061045 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 25 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03061045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing